Skip to content

CIK 0001841125

BSLK Bolt Projects Holdings, Inc.

Insider trading from SEC Form 4. Last filing Dec 31, 2024.

Last 90 days

Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
11
with a Form 4 at this company

Signals

Open-market buys and sells at Bolt Projects Holdings, Inc., scored.

ScoreSideInsiderValueSharesHoldings changePrice contextFiled
25WeaksellGolden Arrow Sponsor, LLC
owner
$253k500,000-5%-

Transactions

The last 26 rows filed, every code.

DateInsiderTransactionSharesPriceValueHoldings afterFiled
Dec 27, 2024Golden Arrow Sponsor, LLC
owner
SOpen-market sale
Common Stock
-221,144$0.50$112k9,441,558Dec 31, 2024
Dec 30, 2024Golden Arrow Sponsor, LLC
owner
SOpen-market sale
Common Stock
-278,856$0.51$142k9,162,702Dec 31, 2024
Dec 4, 2024Befumo Randy
INTERIM CFO
AGrant or award
Common Stock
+147,058$0.34$50k300,045Dec 4, 2024
Dec 4, 2024Breslauer David Nate
CHIEF TECHNOLOGY OFFICER
AGrant or award
Common Stock
+73,529$0.34$25k360,145Dec 4, 2024
Dec 4, 2024Widmaier Daniel Matthew
CHIEF EXECUTIVE OFFICER
AGrant or award
Common Stock
+73,529$0.34$25k468,627Dec 4, 2024
Dec 4, 2024FIDDLER JERRY
director
AGrant or award
Common Stockindirect: BY ZYGOTE VENTURES LLC
+588,235$0.34$200k1,083,694Dec 4, 2024
Dec 4, 2024Finard Jeri B
director
AGrant or award
Common Stock
+176,745$0.34$60k176,475Dec 4, 2024
Nov 25, 2024Nardi Cintia
PRESIDENT
AGrant or award
Option (Right to Buy Common Stock)derivative
+749,250$0.00$0749,250Nov 27, 2024
Nov 25, 2024Naffakh Sami Pascal
director
AGrant or award
Common Stock
+22,500$0.00$022,500Nov 27, 2024
Nov 25, 2024Widmaier Daniel Matthew
CHIEF EXECUTIVE OFFICER
AGrant or award
Option (Right to Buy Common Stock)derivative
+1,200,000$0.00$01,200,000Nov 27, 2024
Nov 25, 2024Breslauer David Nate
CHIEF TECHNOLOGY OFFICER
AGrant or award
Option (Right to Buy Common Stock)derivative
+1,200,000$0.00$01,200,000Nov 27, 2024
Nov 25, 2024FIDDLER JERRY
director
AGrant or award
Common Stock
+22,500$0.00$088,485Nov 27, 2024
Nov 25, 2024KLOSK STEVEN M
director
AGrant or award
Common Stock
+22,500$0.00$057,500Nov 27, 2024
Nov 25, 2024Carpio Ransley Keoni
director
AGrant or award
Option (Right to Buy Common Stock)derivative
+22,500$0.00$022,500Nov 27, 2024
Nov 25, 2024Finard Jeri B
director
AGrant or award
Option (Right to Buy Common Stock)derivative
+22,500$0.00$022,500Nov 27, 2024
Nov 25, 2024Slattery Paul Joseph
GENERAL COUNSEL & SECRETARY
AGrant or award
Common Stock
+40,000$0.00$040,000Nov 27, 2024
Nov 25, 2024Befumo Randy
INTERIM CFO
AGrant or award
Option (Right to Buy Common Stock)derivative
+278,460$0.00$0278,460Nov 27, 2024
Nov 25, 2024Finard Jeri B
director
AGrant or award
Option (Right to Buy Common Stock)derivative
+15,000$0.00$015,000Nov 27, 2024
Nov 25, 2024Carpio Ransley Keoni
director
AGrant or award
Option (Right to Buy Common Stock)derivative
+15,000$0.00$015,000Nov 27, 2024
Nov 25, 2024KLOSK STEVEN M
director
AGrant or award
Common Stock
+15,000$0.00$072,500Nov 27, 2024
Nov 25, 2024Slattery Paul Joseph
GENERAL COUNSEL & SECRETARY
AGrant or award
Option (Right to Buy Common Stock)derivative
+319,680$0.00$0319,680Nov 27, 2024
Nov 25, 2024FIDDLER JERRY
director
AGrant or award
Common Stock
+15,000$0.00$0103,485Nov 27, 2024
Nov 25, 2024Breslauer David Nate
CHIEF TECHNOLOGY OFFICER
AGrant or award
Option (Right to Buy Common Stock)derivative
+319,680$0.00$0319,680Nov 27, 2024
Nov 25, 2024Befumo Randy
INTERIM CFO
AGrant or award
Option (Right to Buy Common Stock)derivative
+239,760$0.00$0239,760Nov 27, 2024
Nov 25, 2024Widmaier Daniel Matthew
CHIEF EXECUTIVE OFFICER
AGrant or award
Option (Right to Buy Common Stock)derivative
+1,018,980$0.00$01,018,980Nov 27, 2024
Nov 25, 2024Naffakh Sami Pascal
director
AGrant or award
Common Stock
+15,000$0.00$037,500Nov 27, 2024

Insiders

Everyone who has filed a Form 4 here.

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.